|By Marketwired .||
|July 30, 2014 05:30 AM EDT||
CAMBRIDGE, MA -- (Marketwired) -- 07/30/14 -- Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, today announced that it has successfully completed a key preclinical milestone in the collaboration with Biogen Idec. Proteostasis has received a multimillion dollar milestone payment as a result of this achievement.
"We are very encouraged to reach this milestone early in our collaboration with Biogen Idec," said Markus Haeberlein, Ph.D., Chief Scientific Officer at Proteostasis Therapeutics. "Achieving a target protein reduction through inhibition of Usp14 in a whole animal system is an important biological validation and demonstrates the disease-modifying potential of our inhibitors against a variety of neurodegenerative disorders. We look forward to continuing to work with Biogen Idec to bring this program toward candidate designation."
Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, have elevated levels of aggregation-prone proteins in the brain. Prior research has shown that the inhibition of the deubiquinating enzyme, Usp14, enhances proteasome activity and increases the clearance of such proteins.
"We remain optimistic about Usp14 as a very interesting and potentially important target for neurodegeneration," said Spyros Artavanis-Tsakonas, Ph.D., Chief Scientific Officer at Biogen Idec.
In December 2013, Proteostasis and Biogen Idec entered into a collaboration to research and develop therapeutic candidates based on the inhibition of Usp14. Under the agreement, the companies are conducting preclinical research to identify lead compounds for clinical development. At specified points, Proteostasis may opt in for global co-development and U.S. co-commercialization rights. The total deal contains payments of up to $200 million, as well as tiered royalties.
About Proteostasis Therapeutics
Proteostasis Therapeutics is developing disease-modifying therapeutics for cystic fibrosis and neurodegenerative diseases. The Company's technology combines both phenotypic and target based drug discovery to develop therapeutics that modulate protein homeostasis pathways and correct for imbalances in protein folding, trafficking, and clearance. For more information, please visit www.proteostasis.com.
Dec. 4, 2016 06:45 AM EST Reads: 1,220
Dec. 4, 2016 06:15 AM EST Reads: 6,950
Dec. 4, 2016 05:30 AM EST Reads: 1,751
Dec. 4, 2016 04:45 AM EST Reads: 4,960
Dec. 4, 2016 04:30 AM EST Reads: 1,553
Dec. 4, 2016 04:30 AM EST Reads: 853
Dec. 4, 2016 04:00 AM EST Reads: 4,953
Dec. 4, 2016 04:00 AM EST Reads: 6,222
Dec. 4, 2016 03:45 AM EST Reads: 1,552
Dec. 4, 2016 02:15 AM EST Reads: 877
Dec. 4, 2016 02:00 AM EST Reads: 3,783
Dec. 4, 2016 12:30 AM EST Reads: 1,787
Dec. 3, 2016 11:00 PM EST Reads: 4,165
Dec. 3, 2016 11:00 PM EST Reads: 968
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
Dec. 3, 2016 09:30 PM EST Reads: 1,777